Rare Variant Burden in ALS Genes Influences Disease Onset

This article originally appeared here.
Share this content:
Rare Variant Burden in ALS Genes Influences Disease Onset
Rare Variant Burden in ALS Genes Influences Disease Onset

FRIDAY, Nov. 21, 2014 (HealthDay News) -- Rare and potentially pathogenic variants in known amyotrophic lateral sclerosis (ALS) genes are present in a considerable proportion of patients with familial and sporadic disease, and the burden of variants influences disease onset, according to a study published online Nov. 7 in the Annals of Neurology.

Janet Cady, from Washington University in St. Louis, and colleagues used targeted pooled-sample sequencing to identify variants in 17 ALS genes from 391 ALS patients in the United States. ATXN2 and C9ORF72 expansion sizes were defined using fragment size analysis. Genotype-phenotype associations were made with individual variant and with total variant burden. At both single variant and gene level, the authors examined rare variant associations for the risk of ALS.

The researchers found that 64.3 and 27.8 percent of familial and sporadic subjects, respectively, carried potentially pathogenic novel or rare coding variants that were identified by sequencing or an expanded repeat in ATXN2 and C9ORF72. Overall, variants in more than one ALS gene were seen in 3.8 percent of subjects, and in these individuals, disease onset occurred more than 10 years earlier (P = 0.0046) compared to those with a variant in a single gene. There was no correlation between the number of potentially pathogenic coding variants and disease duration or site of onset.

"A significant number of subjects carried variants in more than one gene, which influenced the age of symptom onset and supports oligogenic inheritance as relevant to disease pathogenesis," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »